Patten & Patten Inc. TN Sells 700 Shares of Hologic, Inc. (NASDAQ:HOLX)

Patten & Patten Inc. TN lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,198 shares of the medical equipment provider’s stock after selling 700 shares during the period. Patten & Patten Inc. TN’s holdings in Hologic were worth $1,341,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. BKM Wealth Management LLC acquired a new position in Hologic during the fourth quarter valued at approximately $86,000. Yarbrough Capital LLC acquired a new position in shares of Hologic during the 4th quarter worth $355,000. Raymond James & Associates lifted its position in shares of Hologic by 9.9% during the 4th quarter. Raymond James & Associates now owns 276,880 shares of the medical equipment provider’s stock worth $19,783,000 after buying an additional 24,867 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Hologic by 9.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 925,968 shares of the medical equipment provider’s stock valued at $66,160,000 after buying an additional 80,475 shares in the last quarter. Finally, Harrington Investments INC grew its position in Hologic by 4.9% in the fourth quarter. Harrington Investments INC now owns 12,024 shares of the medical equipment provider’s stock valued at $859,000 after acquiring an additional 560 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the transaction, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Trading Up 0.3 %

NASDAQ:HOLX traded up $0.27 during trading hours on Monday, hitting $78.38. 601,500 shares of the company were exchanged, compared to its average volume of 1,621,356. The stock has a market capitalization of $18.29 billion, a price-to-earnings ratio of 39.91, a price-to-earnings-growth ratio of 2.60 and a beta of 0.99. Hologic, Inc. has a one year low of $64.02 and a one year high of $82.45. The company has a fifty day simple moving average of $74.26 and a 200 day simple moving average of $74.82. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned $1.06 earnings per share. The firm’s revenue was down .8% compared to the same quarter last year. Sell-side analysts expect that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research reports. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Friday, May 3rd. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their target price for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Evercore ISI lowered their price target on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating for the company in a report on Tuesday, July 2nd. Finally, Stephens began coverage on Hologic in a report on Thursday, June 27th. They set an “overweight” rating and a $87.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.